WallStreetZenWallStreetZen

NASDAQ: RCEL
Avita Medical Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for RCEL

Based on 3 analysts offering 12 month price targets for Avita Medical Inc.
Min Forecast
$11.00+105.22%
Avg Forecast
$16.03+199.12%
Max Forecast
$25.00+366.42%

Should I buy or sell RCEL stock?

Based on 3 analysts offering ratings for Avita Medical Inc.
Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RCEL stock forecasts and price targets.

Forecast return on equity

Is RCEL forecast to generate an efficient return?
Company
-58.89%
Industry
24.32%
Market
118.57%
RCEL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RCEL forecast to generate an efficient return on assets?
Company
-53.09%
Industry
13.22%
RCEL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RCEL earnings per share forecast

What is RCEL's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.29
Avg 2 year Forecast
-$1.29
Avg 3 year Forecast
-$1.34

RCEL revenue forecast

What is RCEL's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$30.1M-5.03%
Avg 2 year Forecast
$36.0M+13.46%
Avg 3 year Forecast
$36.0M+13.68%
RCEL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RCEL revenue growth forecast

How is RCEL forecast to perform vs Medical Devices companies and vs the US market?
Company
5.29%
Industry
4.76%
Market
8.46%
RCEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RCEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RCEL vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
RCEL$5.36$16.03+199.12%Strong Buy
STXS$1.75$9.00+414.29%Strong Buy
QIPT$4.18$7.50+79.43%Strong Buy
RPID$3.49N/AN/AHold
OWLT$1.04$4.38+320.67%Hold

Avita Medical Stock Forecast FAQ

Is Avita Medical Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RCEL) stock is to Strong Buy RCEL stock.

Out of 3 analysts, 3 (100%) are recommending RCEL as a Strong Buy, 0 (0%) are recommending RCEL as a Buy, 0 (0%) are recommending RCEL as a Hold, 0 (0%) are recommending RCEL as a Sell, and 0 (0%) are recommending RCEL as a Strong Sell.

If you're new to stock investing, here's how to buy Avita Medical stock.

What is RCEL's earnings growth forecast for 2022-2023?

(NASDAQ: RCEL) Avita Medical's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 19.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Avita Medical's earnings in 2022 is -$30,151,000.On average, 3 Wall Street analysts forecast RCEL's earnings for 2022 to be -$32,253,984, with the lowest RCEL earnings forecast at -$33,254,107, and the highest RCEL earnings forecast at -$31,503,891. On average, 1 Wall Street analyst forecast RCEL's earnings for 2023 to be -$32,253,984, with the lowest RCEL earnings forecast at -$32,253,984, and the highest RCEL earnings forecast at -$32,253,984.

In 2023, RCEL is forecast to generate -$33,504,138 in earnings, with the lowest earnings forecast at -$39,004,817 and the highest earnings forecast at -$28,753,551.

What is RCEL's revenue growth forecast for 2022-2023?

(NASDAQ: RCEL) Avita Medical's forecast annual revenue growth rate of 5.29% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Avita Medical's revenue in 2022 is $31,695,000.On average, 1 Wall Street analysts forecast RCEL's revenue for 2022 to be $752,592,949, with the lowest RCEL revenue forecast at $752,592,949, and the highest RCEL revenue forecast at $752,592,949. On average, 1 Wall Street analysts forecast RCEL's revenue for 2023 to be $899,111,044, with the lowest RCEL revenue forecast at $899,111,044, and the highest RCEL revenue forecast at $899,111,044.

In 2023, RCEL is forecast to generate $900,861,261 in revenue, with the lowest revenue forecast at $900,861,261 and the highest revenue forecast at $900,861,261.

What is RCEL's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: RCEL) forecast ROA is -53.09%, which is lower than the forecast US Medical Devices industry average of 13.22%.

What is RCEL's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RCEL price target, the average RCEL price target is $16.03, with the highest RCEL stock price forecast at $25.00 and the lowest RCEL stock price forecast at $11.00.

On average, Wall Street analysts predict that Avita Medical's share price could reach $16.03 by Aug 15, 2023. The average Avita Medical stock price prediction forecasts a potential upside of 199.12% from the current RCEL share price of $5.36.

What is RCEL's Earnings Per Share (EPS) forecast for 2022-2023?

(NASDAQ: RCEL) Avita Medical's current Earnings Per Share (EPS) is -$1.21. On average, analysts forecast that RCEL's EPS will be -$1.29 for 2022, with the lowest EPS forecast at -$1.33, and the highest EPS forecast at -$1.26. On average, analysts forecast that RCEL's EPS will be -$1.29 for 2023, with the lowest EPS forecast at -$1.29, and the highest EPS forecast at -$1.29. In 2023, RCEL's EPS is forecast to hit -$1.34 (min: -$1.56, max: -$1.15).

What is RCEL's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: RCEL) forecast ROE is -58.89%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.